A comprehensive view of Generics / Biosimilars. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.
Vanda Pharmaceuticals' attempts to uphold patents for circadian rhythm drug Hetlioz denied by the US Supreme Court; the decision follows an earlier legal loss against generic drug manufacturers Teva and Apotex & an FDA rejection of Hetlioz usage expansion
Published:
April 23, 2024
by FiercePharma
|
NH HB1365: Relative to substitution of biological products by pharmacies.
Published:
April 18, 2024
by New Hampshire 2024 Regular Session
|
AK SB121: Pharmacies/pharmacists/benefits Managers
Published:
April 17, 2024
by Alaska 33rd Legislature
|
IL SB2672: INS CD-GENERIC DRUG SHORTAGE
Published:
April 16, 2024
by Illinois 103rd General Assembly
|
ME LD2114: Resolve, Directing the Superintendent of Insurance to Collect Data from Health Insurers Related to Prescription Drug Coverage of Generic Drugs and Biosimilars
Published:
April 11, 2024
by Maine 131st Legislature
|
Ask us about our Government & Public Policy market view